PRMT5:MEP50 Interaction Inhibitors for Selective Cancer Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for cancer, particularly prostate cancer, face challenges due to PRMT5-mediated therapy resistance and overexpression, which is often associated with poor clinical outcomes, necessitating a targeted approach to inhibit the PRMT5:MEP50 protein-protein interaction for specific and selective therapeutic compounds.
Innovation Solution
Development of compounds that inhibit the PRMT5:MEP50 protein-protein interaction, specifically through the design and synthesis of inhibitors targeting the interface residues of PRMT5 and MEP50, such as compound 17, which disrupts the interaction and reduces the activity of PRMT5 in cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PRMT5 catalytic activity is inhibited, then cancer cell growth is suppressed, but other methyltransferases are also affected causing non-specific effects
Solution Approach 1:
The patent segments the PRMT5 complex into two distinct targets: the catalytic site and the MEP50 cofactor binding interface. By developing inhibitors that specifically target the PRMT5:MEP50 protein-protein interaction interface rather than the catalytic site, the invention achieves selective inhibition of PRMT5 without affecting other SAM-dependent methyltransferases that share the same catalytic mechanism but have different cofactor requirements.
Solution Approach 2:
The patent uses MEP50 as an intermediary target to achieve specific PRMT5 inhibition. Instead of directly inhibiting PRMT5 catalytic activity, the compounds disrupt the protein-protein interaction between PRMT5 and its obligate cofactor MEP50. This intermediary approach allows selective targeting of PRMT5 since MEP50 is unique to PRMT5 among the PRMT family, thereby avoiding off-target effects on other methyltransferases.
2Reliability
If pan-MT inhibitors are used, then PRMT5 activity is reduced, but non-specific targeting of other methyltransferases occurs
Solution Approach 1:
The patent applies local quality by designing compounds that specifically target the unique structural features of the PRMT5:MEP50 interaction interface. The inhibitors are structured to bind to residues at the protein-protein interface that are specific to PRMT5-MEP50 binding, rather than targeting the conserved catalytic site. This localized targeting approach ensures high specificity for PRMT5 while leaving other methyltransferases unaffected.
Solution Approach 2:
The patent employs MEP50 binding interface as an intermediary target to achieve specific PRMT5 inhibition without affecting other methyltransferases. Since MEP50 is an obligate and unique cofactor for PRMT5, disrupting the PRMT5:MEP50 interaction provides a selective approach that avoids the non-specific effects associated with pan-MT inhibitors that target the conserved catalytic site shared by all PRMT family members.
3Adaptability or versatility
If PRMT5 is targeted in all cancers, then broad coverage is achieved, but context-specific dependency is ignored reducing efficacy
Solution Approach 1:
The patent introduces dynamics by enabling selective targeting of PRMT5 in cancer contexts where PRMT5:MEP50 dependency is highest. Rather than applying a static one-size-fits-all approach to all cancers, the therapy can be adapted to target specific cancer types or stages that exhibit high dependency on the PRMT5:MEP50 interaction, such as prostate cancer and other cancers with elevated PRMT5 expression and MEP50 dependency.
Solution Approach 2:
The patent applies local quality by identifying and targeting specific cancer contexts where PRMT5:MEP50 interaction is critically important for tumor survival and progression. The therapy is optimized for cancers with high PRMT5 expression and dependency on MEP50 cofactor function, such as prostate cancer, rather than uniformly applying to all cancer types. This context-specific approach maximizes therapeutic efficacy where the target is most relevant.
Data Source
AI summary
Disclosed are inhibitors of a protein-protein interaction between protein arginine methyltransferase 5 (PRMT5) and methylosome protein 50 (MEP50) based on isoxazolyl methoxyphenyl derivatives. Further disclosed are pharmaceutical compositions comprising PRMT5:MEP50 inhibitors and methods of inhibiting protein arginine methyltransferase 5 (PRMT5) using PRMT5.MEP50 inhibitors or pharmaceutical compositions comprising PRMT5:MEP50 inhibitors.